|
KMID : 1036520210110010008
|
|
Clinical Neuro-Ophthalmology
2021 Volume.11 No. 1 p.8 ~ p.11
|
|
|
New Treatment of Thyroid Eye Disease
|
|
Kwon Eun-Jin
|
|
|
Abstract
|
|
|
|
Thyroid associated ophthalmopathy, thyroid eye disease (TED) is a relatively rare condition, associated with autoimmune disease. The manifestation is divided into two phases, active and inactive phase, according to the inflammation involved. In the orbital fibroblast, the inflammation pathway triggered by autoantibody makes the muscle volume expanded. The proptosis and diplopia is the most common and critical sign and symptom in TED. So far, there has not been long-term disease-modifying treatment. Intravenous steroid and immune suppressant had short-term relief. Because of the lack of treatment alternatives, physicians dismiss or minimize the complaints from the TED patients. Proptosis and diplopia impact quality of life and socioeconomic status. Lately, the study of the Teprotumumab (anti-IGF-1R Antibody) had shown the improvement of proptosis and diplopia in moderate to severe TED patients. We hope Teprotumumab would be the milestone of the new era of treatment in TED.
|
|
|
KEYWORD
|
|
|
Thyroid eye disease, Thyroid-associated ophthalmopathy, Grave’s ophthalmopathy, Teprotumumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|